Related Experiment Video

Updated: May 26, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

New generation small-molecule inhibitors in myeloproliferative neoplasms

Francesco Passamonti1, Margherita Maffioli, Domenica Caramazza

  • 1Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy. francesco.passamonti@ospedale.varese.it

Current Opinion in Hematology
|January 10, 2012
PubMed
Abstract

Insights

Recent advances in myeloproliferative neoplasms (MPNs) therapy focus on JAK2 inhibitors. These treatments effectively reduce spleen size and constitutional symptoms in patients with MPNs carrying the JAK2 mutation.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by the JAK2 (V617F) mutation in approximately 70% of cases.
  • Understanding the molecular pathways driving MPN development is crucial for therapeutic advancements.

Purpose of the Study:

  • To review recent therapeutic progress in MPNs, specifically focusing on the role and efficacy of JAK2 inhibitors.
  • To highlight novel therapeutic strategies targeting key molecular pathways in MPN.

Main Methods:

  • Review of current investigations into drugs targeting JAK-STAT, PI3K/AKT/mTOR, and epigenetic pathways.
  • Analysis of clinical trial data and research findings on JAK2 inhibitors and other novel agents.

Main Results:

  • Several JAK2 inhibitors (e.g., ruxolitinib, TG101348) and other targeted therapies (e.g., everolimus, givinostat) are under investigation.
  • Significant improvements observed include reduction in spleen size and alleviation of constitutional symptoms in MPN patients.

Conclusions:

  • JAK2 inhibitors are most beneficial for MPN patients with splenomegaly or constitutional symptoms.
  • Patients with lower hemoglobin levels should be informed about the potential temporary increase in red blood cell transfusion needs with these therapies.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...